-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2180 Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, Adult, Clinical Research, Diseases, Registries, Myeloid Malignancies, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Yishan Ye, MD1*, Allain Thibeault Ferhat Berland2*, Myriam Labopin3*, Jia Chen4*, Depei Wu, MD, PhD5, Didier Blaise, MD6*, Emanuele Angelucci, MD7, Edouard Forcade, MD, PhD8*, Xiao-Jun Huang, MD9, Ibrahim Yakoub-Agha, MD, PhD10*, Urpu Salmenniemi, MD11*, Patrice Chevallier, MD, PhD12, Ali Bazarbachi, MD, PhD13, Arnon Nagler, MD14, Eolia Brissot15, Lin Li16*, Yi Luo17, Yanmin Zhao, MD1*, Fabio Ciceri18*, He Huang19*, Mohamad Mohty, MD, PhD20 and Norbert Claude Gorin Sr.21

1Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2EBMT Paris study office, Paris, France
3EBMT Statistical Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
4The First Affiliated Hospital of Soochow University, Suzhou, China
5Department of Hematology, the First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China
6Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Marseille, France
7Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, ITA
8Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
9Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
10CHU de Lille, Université de Lille, INSERM U1286, Infinite, 59000, Lille, France
11HUCH Comprehensive Cancer Center, Helsinki, Finland, Helsinki, Finland
12Hematology Department, Nantes University Hospital, Nantes, France
13American University of Beirut Dept. of Medicine, Beirut, Lebanon
14Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv, Israel
15Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France, Paris, France
16The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
17Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Bone Marrow Transplantation, the First Affiliated Hospital of Zhejiang Universit, Hangzhou, China
18Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan, Italy
19Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
20Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
21Department of Hematology and Cell therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France

Background

Matched sibling donor (MSD) remains to date the first choice for allogeneic hematopoietic cell transplantation (allo-HCT). Haploidentical donors (HAPLO) have surged up as important alternative whose therapeutic effects might be similar to 10/10 matched unrelated donor (MUD). Donor age has been associated with worse outcomes after allo-HCT mainly due to higher rate of graft-versus-host disease (GvHD). We compared in an EBMT global multi-center registry-based analysis the outcomes following allo-HCT from younger HAPLO or older MUD.

Methods

Data of 4205 adult AML patients receiving a first allo-HCT in CR1 from between 2010 and 2022 were analyzed. Transplants from mismatched UD (<10/10) were excluded. Statistical analysis included univariable and multivariable analysis (MVA) adjust for potential confounding factors using a Cox proportional-hazards regression model for main outcomes.

Results

Data of 2651 patients receiving younger HAPLO (15-40 years old(yo)) and 1554 patients receiving older MUD (40-65yo) HCTs were analyzed. For the entire cohort, median patient age was 55.6y (range: 18-75), and the disease risk classification distribution was similar between the two groups according to the ELN 2022 criteria. More patients in the younger HAPLO group received myeloablative conditioning (65%) than in the older MUD group (50%, p<0.001). For GVHD prophylaxis, post-transplant cyclophosphamide was the major regimen for younger HAPLO (66%) while ATG served as backbone for older MUD (92%). The median follow-up was 2.5 years (interquartile range, IQR= 2.3 - 2.6) for younger HAPLO and 3.7 years (IQR= 3.3 - 4) for older MUD.

We found that the proportion of patients with a Karnofsky >=90 was higher for older MUD. To avoid any bias due to this interaction between variable, we separated the analysis according to the Karnofsky score (> =90 and <90) during multivariate analysis.

On multivariable analysis, for patients with Karnofsky score > =90, older MUD was associated with higher RI (hazard ratio [HR]=1.36, 95% CI 1.14-1.63; p=0.001, younger HAPLO as reference) and higher extensive cGVHD incidence (HR=1.73, 95% CI 1.34-2.24; p<0.001) compared to younger HAPLO, leading to worse LFS (HR=1.16, 95% CI 1.01-1.33; p=0.032). For patients with Karnofsky score <90, older MUD was associated with higher overall (HR=1.44, 95% CI 1.05-1.98; p=0.025) and extensive cGVHD incidences (HR=1.88, 95% CI 1.18-2.99; p=0.008). Although older MUD was associated with better NRM compared to younger HAPLO (HR=0.72, 95% CI 0.52-1; p=0.048), no significant difference was between the two groups concerning LFS and OS.

Additionally, adverse ELN2022 cytogenetics was associated with higher RI, poorer LFS and OS. Older patient age (per 10 years) was associated with higher NRM, which led to inferior LFS and OS, for patients with Kanorfsfy score <90 and >=90.

Conclusions

Younger haploidentical donors might be superior to older matched unrelated donors AML patients allografted in CR1 due to lower RI and extensive cGVHD incidences, especially for patients with Karnofsky >=90.

Disclosures: Angelucci: Novartis: Honoraria; Menarini: Honoraria, Speakers Bureau; Sanofi: Honoraria; BMS: Other: DMC; Vertex: Other: DMC; Regeneron: Honoraria; Vifor: Other: DMC. Forcade: Sanofi: Other: Travel support, Speakers Bureau; Novartis: Other: Travel support, Speakers Bureau; Jazz: Speakers Bureau; GSK: Speakers Bureau; Gilead: Other: Travel support, Speakers Bureau; Astellas: Research Funding; Alexion: Other: Travel support, Speakers Bureau; Maat Pharma: Consultancy; Novartis: Consultancy; Sobi: Speakers Bureau. Yakoub-Agha: Kite, a Gilead Company: Honoraria, Other: Travel Support; Bristol Myers Squibb: Honoraria; Novartis: Honoraria; Janssen: Honoraria. Salmenniemi: Medac: Consultancy; Astella: Other: advisory board; Takeda: Other: Advisory board; AstraZeneca: Other: Advisory board; Immdica: Other: Advisory board. Bazarbachi: Caribou: Honoraria; Jansen: Honoraria, Research Funding; Amgen: Honoraria; Pfizer: Research Funding; Takeda: Honoraria; Roche: Honoraria, Research Funding; Biologix: Research Funding. Mohty: Takeda: Honoraria; Novartis: Honoraria; Stemline Menarini: Honoraria; Pfizer: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Research Funding, Speakers Bureau; Jazz: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria; Adaptive: Honoraria; GSK: Honoraria; Amgen: Honoraria; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; MaaT Pharma: Current equity holder in publicly-traded company.

*signifies non-member of ASH